Arbutus Biopharma Reports Q1 Loss, Misses Revenue Estimates
| ABUS Stock | USD 3.46 0.01 0.29% |
Slightly above 61% of Arbutus Biopharma's investor base is looking to short. The analysis of the overall investor sentiment regarding Arbutus Biopharma Corp suggests that many traders are alarmed. Arbutus Biopharma's investing sentiment can be driven by a variety of factors including economic data, Arbutus Biopharma's earnings reports, geopolitical events, and overall market trends.
Arbutus |
Arbutus delivered earnings and revenue surprises of 0 percent and 28.91, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock
Read at finance.yahoo.com
 |
Arbutus Biopharma Fundamental Analysis
We analyze Arbutus Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arbutus Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arbutus Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Arbutus Biopharma is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Arbutus Biopharma Corp Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Arbutus Biopharma stock to make a market-neutral strategy. Peer analysis of Arbutus Biopharma could also be used in its relative valuation, which is a method of valuing Arbutus Biopharma by comparing valuation metrics with similar companies.
Peers
Arbutus Biopharma Related Equities
| AFMD | Affimed NV | 1.05 |
| ||
| ADAP | Adaptimmune Therapeutics | 1.37 |
| ||
| CRVS | Corvus Pharmaceuticals | 3.50 |
| ||
| ADMA | ADMA Biologics | 7.88 |
|
Additional Tools for Arbutus Stock Analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.